Clinical Trials Sponsored by CSL Behring

Total 4223 results

CSL Behring
CSL Plasma

Completed

Rabies Immune Plasma Booster Study

Rabies

United States
CSL Behring

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B

United States, Canada
CSL Behring

Recruiting

Observatory of Patients With Haemophilia B Treated by IdElvion® (OrPHEe)

Haemophilia B

France
CSL Behring

Recruiting

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
CSL Behring

Recruiting

Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States
CSL Behring

Active, not recruiting

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Hemophilia B

Netherlands, Germany
CSL Behring

Enrolling by invitation

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

Hemophilia B

United States
CSL Behring

Active, not recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

End Stage Kidney Disease | Atherosclerotic Cardiovascular Disease

United States, Australia, Belgium, Canada, Germany
CSL Behring

Completed

Registry of Patients With Von WilLEbrand Disease Treated With Voncento® (OPALE)

Von Willebrand Disease

France
CSL Behring

Completed

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

Asthma

United Kingdom, Germany
CSL Behring

Completed

Effects of CSL324 in the Lung After Segmental Challenge

Healthy Volunteers

Germany
CSL Behring

Completed

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Acute Coronary Syndrome

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvi... and more
CSL Behring

Completed

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Hereditary Angioedema

United States, Germany, Japan, Hungary, Canada, Netherlands, Israel
CSL Behring

Completed

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema

Canada, Australia, Germany, United States, Israel
CSL Behring

Completed

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

Healthy

Australia
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
CSL Behring

Completed

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Acute Myocardial Infarction

United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
CSL Behring

Terminated

Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1)

Chronic Inflammatory Demyelinating Polyneuropathy

France
CSL Behring

Withdrawn

CSL324 in COVID-19

Coronavirus Disease 2019 (COVID-19)
CSL Behring

Completed

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Acute Myocardial Infarction | Moderate Renal Impairment

United States, Germany, Hungary, Israel, Netherlands
CSL Behring

Completed

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
CSL Behring

Completed

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Primary Immune Deficiency | Secondary Immune Deficiency

Canada
CSL Behring

Completed

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Acute Myocardial Infarction

Germany, United Kingdom
CSL Behring

Completed

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Hereditary Angioedema Types I and II

Bulgaria, Hungary, Poland, Romania
CSL Behring

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Emphysema | Alpha 1-proteinase Inhibitor Deficiency

Australia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
CSL Behring

Completed

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

Hemophilia A

Canada
CSL Behring

Completed

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Multifocal Motor Neuropathy (MMN)

Switzerland, Italy, United Kingdom
CSL Behring

Completed

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Hereditary Angioedema Types I and II

Germany
CSL Behring

Completed

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States, Spain
CSL Behring

Completed

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Cystic Fibrosis

Bulgaria, Hungary, Poland, United Kingdom
CSL Behring

Completed

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Von Willebrand Disease

Canada
CSL Behring

Completed

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Primary Immune Deficiency

United States
CSL Behring

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (IX-TEND 4001)

Hemophilia B

United States
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
CSL Behring

Recruiting

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Traumatic Injury

United States, United Kingdom, Australia
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
CSL Behring

Completed

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Canada, United Kingdom, Australia, Germany, Poland, Belgium, Austria, Denmark, Italy, Spain
CSL Behring

Completed

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Australia, Germany, Poland, Italy, United Kingdom
CSL Behring

Completed

Dose Confirmation Trial of AAV5-hFIXco-Padua

Hemophilia B

United States
CSL Behring

Completed

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Sickle Cell Disease

United States, United Kingdom, Netherlands
CSL Behring

Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Hidradenitis Suppurativa | Palmoplantar Pustulosis

Denmark, Australia, Germany
CSL Behring

Active, not recruiting

Register of Patients With haEmophilia A tReated With Afstyla® (OPERA)

Haemophilia A

France
CSL Behring

Completed

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Healthy Participants

United States
CSL Behring

Terminated

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Coronavirus Disease 2019 (COVID-19)

Australia

Clinical Trials Sponsored by CSL Behring

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations